ORICORIC Pharmaceuticals, Inc.
$12.01-16% 1Y
$12.01
$7.4752 weeks$14.67
Price
-16%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 3% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for ORIC today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$1.24B
1 year-16%
5 years-41%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates.Earnings release · press release
- Jul 30, 2026Effective July 28, 2026, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), in order to increase the number of shares reserved for issuance under the …Director or officer change · Form 8-K
- Jun 22, 2026ORIC Pharmaceuticals, Inc. (the “Company”) amended and restated its 2020 Equity Incentive Plan (the “A&R 2020 Equity Incentive Plan”), effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.